Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.11 -0.35 (-0.71%)
Official Closing Price Updated: 7:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial. 
Via Benzinga
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary
Eli Lilly’s Zepbound led to 47% greater weight loss than Wegovy in a 72-week trial, yet retail sentiment turned bearish on Stocktwits amid heightened scrutiny on drug pricing following Trump’s vow to... 
Via Stocktwits
Topics Government
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%. 
Via Benzinga
Topics Government
Deal Dispatch: Nestlé, Coinbase, OpenAI Lead Diverse M&A Lineup As WeightWatchers Goes Bankrupt
With water scarcity, AI acceleration, and GLP-1 drugs reshaping demand, deal professionals are sprinting to adapt. 
Via Benzinga
Topics Artificial Intelligence
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Hims & Hers Stock's 100% Surge Is Squeezing Shorts And It Might Just Be Getting Started
Hedge funds shorting Hims & Hers Health Inc (NYSE:HIMS) may regret it - earnings with a positive surprise could lead to a short squeeze as stock continues to rise, up 96% in past month. 
Via Benzinga
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential. 
Via Benzinga
Topics ETFs Government
Investors should take note of NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a growth stock that remains attractively priced.
NOVO-NORDISK A/S-SPONS ADR could be undervalued. NYSE:NVO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
Hims & Hers Has a Superpower in Healthcare
This isn't just any growth stock. 
Via The Motley Fool
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Via The Motley Fool
Topics Earnings Government World Trade
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its... 
Via Benzinga
Why Novo Nordisk Stock Popped After Earnings
Buying Novo Nordisk stock looks like the cheapest way to invest in GLP-1 drugs. 
Via The Motley Fool
Novo Nordisk Predicts Strong Second Half
Via The Motley Fool
Novo Nordisk Stock Rises Pre-Market On Q1 Beat Despite Lowering Outlook – Retail’s Elated
Sales of Novo Nordisk’s flagship weight loss drug Wegovy surged 85% in the first quarter of the fiscal year 2025, while its diabetes treatment Ozempic posted an 18% increase. 
Via Stocktwits
Topics Earnings Law Enforcement
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid GLP-1 competition. 
Via Benzinga
Topics Earnings
Novo Blames Compounders As It Cuts 2025 Forecast. Shares Jump.
Novo Nordisk stock jumped early Wednesday despite cutting its 2025 view. 
Via Investor's Business Daily
Hims & Hers Jumps 18.2% on Incredible 111% Revenue Growth
Hims & Hers is on fire right now. 
Via The Motley Fool
Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Novo Nordisk's Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed
Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments. 
Via Benzinga
Despite Bruce Galloway's Pushback On Bankruptcy, WeightWatchers Enters Chapter 11; Says Members Won't Be Affected
Once a dominant force in the weight-loss industry, WW International Inc. (NASDAQ: WW), formerly known as WeightWatchers, is feeling pressure from the disruptive rise of anti-obesity drugs, and is now... 
Via Benzinga
Topics Bankruptcy
Why Hims & Hers Stock Popped Tuesday, but Eli Lilly and Novo Nordisk Dropped
Good news for Hims & Hers stock spooks Lilly and Novo investors. 
Via The Motley Fool
Topics Earnings
Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant? 
Via MarketBeat
Topics Earnings
Novo Nordisk's Options: A Look at What the Big Money is Thinking
 
Via Benzinga
Top 1% Stock, Hims & Hers Health, Dives On Lackluster Outlook
The company recently inked a deal with Novo Nordisk. But will that bolster current-quarter sales? 
Via Investor's Business Daily
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Via The Motley Fool
Hims & Hers Names New COO. Stock Rallies.
Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas. 
Via Benzinga
3 No-Brainer Stocks to Buy in May
Via The Motley Fool
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
Amgen's Better Than Expected Q1 Earnings Take Backseat As Eyes Are On MariTide Obesity Data
Analysts highlight MariTide's upcoming updates and near-term catalysts, while Amgen's price targets shift amid steady outlook and investor caution. 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.